Faron Announces Positive BEXMAB Study Update
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients Bexmarilimab produces a 50% remission rate in doublet dose cohorts (11 out of 22 patients) Eight of the 11 patients are Complete Responders (CR) or CR with incomplete blood recovery (CRi) Highest overall response rate (ORR) of 80% observed in prior HMA-failure MDS group (4 out of 5 patients) Bexmarilimab continues to be well-tolerated with no dose-limiting